Abstract 16325: Short-Term Changes in Carotid Artery Inflammation Measured by Positron Emission Tomography are Associated With Long Term Atherosclerosis Progression Measured by Magnetic Resonance Imaging
Introduction: It is unknown whether short-term changes arterial wall inflammation are associated with changes in the rate of structural progression of atherosclerosis.
Hypothesis: We assessed arterial inflammation, using positron emission tomography (PET) imaging and 18F-fluorodeoxyglucose (FDG) to test the hypothesis that short term changes in arterial inflammation predict long term atherosclerosis progression, measured by magnetic resonance imaging( MRI).
Methods: Forty-two participants enrolled in the dal-PLAQUE study , who underwent both PET and MRI imaging of the carotid arteries were evaluated. Short-term change in arterial inflammation was measured as change in the carotid FDG target to background ratio [TBR] by PET between baseline and 6 months. The long-term rate of atherosclerotic plaque progression was assessed using MRI, as percent change in carotid mean wall area [MWA] and mean wall thickness [MWT] between baseline and 24 months.
Results: The mean age of the population was 62.5 years, and 12 (28.6 %) were male. In participants with (vs. without) any increase in arterial inflammation over 6 months, long-term rate of change in MWT was significantly higher (% change MWT: 17.49% vs. 1.74%, p=0.038) and long-term rate of change in MWA was significantly higher (% change MWA: 25.50% vs. 3.59%, p = 0.027). Results remained significant after adjusting for clinical and biochemical covariates. Individuals with no increase in arterial inflammation over 6 months had no significant structural progression of atherosclerosis over 24 months, measured as MWT (p=0.616) or MWA (p=0.373).
Conclusions: Short-term changes in arterial inflammation predict long-term atherosclerosis progression. In those with no increase in arterial inflammation, no significant changes in atherosclerosis progression were observed.
Author Disclosures: A. Ishai: None. P. Joseph: None. V. Mani: None. D. Kallend: Employment; Significant; The Medicines Company. Ownership Interest; Significant; The Medicines Company. J. Rudd: None. Z. Fayad: Research Grant; Significant; Roche. A. Tawakol: Research Grant; Significant; Actelion,Genenech,Takeda. Consultant/Advisory Board; Modest; Amgen, Astra, Zeneca, Takeda.
- © 2015 by American Heart Association, Inc.